We are recommending Skye Bioscience Inc. (SKYE) as our next investment opportunity in treating metabolic disease/obesity. Skye is developing a peripheral restricted CB1 antibody — nimacimab — to treat ...
The move for Embark Biotech comes shortly after Novo Nordisk agreed to acquire Inversago and its peripherally acting CB1 receptor (CB1r) blocker therapies for up to $1.075 billion. The lead ...
‘…acute psychotic reactions, generally lasting but a few hours, but occasionally as long as a week; the reaction seemed dose-related and its main features ...
Sarah’s Blessing CBD Gummies are high-end wellness supplement goodness that help promote natural stress-relieving effects while reducing anxiety and pain along with sleep disorders, all by coming from ...